Faculty – Medical Affairs & Communications Launch Readiness Summit


Kavita Aggarwal
Vice President, Medical Affairs, DOVA PHARMACEUTICALS


Richa Attre
Associate Director, Publications Management, Medical Affairs, REGENERON PHARMACEUTICALS

view speaker profile

Richa Attre is the Associate Director, publications & medical communications, Medical Affairs at Regeneron Pharma developing.

Richa completed M.Phil. in Biochemistry and PhD. in Molecular Cell Biology from University of Cambridge, UK; post-doctoral fellowship in microbiology and immunology at Stanford Medical School, CA; MBA at UConn and is completing MPH at Yale.

Previously, Richa worked in medical publications, strategic planning, and scientific communications for about 18 years as scientific team lead/medical director at pharmaceutical, biotechnology industry and medical communications agencies. Richa has experience in several therapy areas, eg autoimmune diseases, cardiovascular, dermatology, gastrointestinal, genomics, hematology, hepatitis C, infectious disease, inflammation, metabolic diseases, musculoskeletal, nephrology, neurology, nutraceuticals, oncology, ophthalmology, orphan diseases, pain, respiratory diseases, surgery, vaccines.

Earlier, Richa was an adjunct faculty at UConn. Richa worked as senior scientist in clinical R&D where she helped develop genomic detection diagnostic kits.

Richa volunteers on a local hospital’s institutional review board and mentors high school students.


Meghan Bagshaw
Director, Global Medical Affairs, SAGE THERAPEUTICS

view speaker profile

I am currently leading the Communications and Operations function within GMA at Sage, a US based biotech that recently launched their first product in the US. As head of GMA Communications & Operations, I am responsible for Med Info, Publications, Med Comms and Operations (inclusive of the Medical Review and Operational support of MLR Review of non-promotional materials). I have held various roles within Medical Affairs over the past 10 years, and got my start in industry via the Investigator Initiated Research Program at Takeda. Prior to industry, I’ve held various research management roles at Dana Farber Cancer Institute and Univ California San Francisco.


Rebecca Burnett
Executive Director and Head of Strategic Services, FRAMEWORK SOLUTIONS

view speaker profile

In her current role as Executive Director and Head of Strategic Services for Framework Solutions, Rebecca Burnett has more than 17 years of biopharmaceutical industry experience. She was most recently the Head of North America Marketing Operations for Mylan where she was responsible for leading her team in the support of five business units and more than 1,400 products.

Ms. Burnett began her career as a clinical research associate and held numerous roles in clinical research and medical affairs before finding her true passion in advertising and promotional review management in 2008. Since that time she has worked with and led teams across a spectrum of biopharmaceutical companies. Her teams have won industry awards for excellence in implementing technology solutions to drive process review efficiency and optimization. Her expertise is in diagnosing and providing recommendations to promotional review teams to ensure compliant and efficient review processes.

Ms. Burnett received her undergraduate and masters degree from the University of Colorado and has an MBA from George Washington.


Jason Crompton, Pharm.D.
Associate Director, Global Scientific Communications Head, Neurodegeneration and Pipeline Scientific Communications, BIOGEN

view speaker profile

Jason Crompton is currently Head of Neurodegeneration and Pipeline Scientific Communications at Biogen. Jason joined Biogen in 2014 as a Medical Communications lead on TECFIDERA moving on to become Scientific Communications lead for ZINBRYTA and SPINRAZA and their launches in multiple sclerosis and spinal muscular atrophy, respectively. In his current role, Jason leads the global team responsible for publications and field medical resources for multiple therapeutic areas including dementias, acute neurology, movement disorders, ophthalmology, and pain. Prior to Biogen, Jason held positions in field medical, medical affairs strategy and medical information at Cubist Pharmaceuticals with a focus in infectious diseases. Jason is a clinical pharmacist by training having practiced in the areas of abdominal and cardiothoracic solid organ transplant.


Howard Dorfman
Adjunct Professor, SETON HALL UNIVERSITY SCHOOL OF LAW

Founder, H.L. DORFMAN CONSULTING

view speaker profile

HOWARD L. DORFMAN is Founder of H.L. Dorfman Pharmaceutical Consulting, LLC, which provides compliance, regulatory, and risk management consulting services to pharmaceutical and biotech companies and law firms. In addition, he is an Adjunct Professor and Distinguished Practitioner in Residence at Seton Hall Law School, where he teaches courses on FDA Law and related subjects in the Health Law and Healthcare Compliance programs. Previously, Mr. Dorfman served in various senior capacities in national and international pharmaceutical and biotech companies. He served as Vice President and General Counsel at Ferring Pharmaceuticals, Inc. in Parsippany, New Jersey, where he was responsible for all legal matters relating to the U.S. affiliate of the Swiss-based global pharmaceutical and biotech company. Previously he served as Counsel in the Life Sciences group at Ropes & Gray LLP in New York, where his practice focused on providing legal and compliance representation to the pharmaceutical, medical device, and biotech industries.

Mr. Dorfman’s areas of expertise include FDA regulatory law, fraud and abuse, healthcare compliance programs, risk management processes, corporate governance, and product liability. Prior to his time at Ropes & Gray, he was chief legal officer of the pharmaceutical division of Bayer Healthcare LLC, where he was responsible for legal oversight relating to the commercial, regulatory, and compliance activities of the company’s U.S. pharmaceutical operations. Before joining Bayer, he worked at Bristol-Myers Squibb (BMS) where he served as Counsel in the Litigation department and subsequently as Counsel to the company’s U.S. pharmaceutical operations.

Mr. Dorfman has established compliance processes and SOPs across a wide range of issues including advertising and promotional review and interactions with healthcare professionals and provides counseling on regulatory, compliance and risk management issues to global, national and start-up companies in the healthcare field as well as advising companies on compliance with the Foreign Corrupt Practices Act (FCPA). He has lectured nationally and published articles on a range of regulatory, compliance and product liability issues. Mr. Dorfman received his B.A. with honors from Yeshiva University and his J.D. from Brooklyn Law School.


Peter L. Goldberg, Ph.D.
Field Medical Strategist — Rheumatology, East U.S. Immunology Patient Value Unit, U.S. Medical Affairs, UCB

view speaker profile

Peter L. Goldberg, PhD. is a highly motivated Field Medical Affairs professional and innovative leader with extensive experience in linking customer needs with company strategy and development opportunities. Proven professional experience in Pharmaceutical Medical Affairs and Leadership with abilities in strategic planning, field associate mentoring/coaching, aligning resources for maximum impact, and change management for the past 15 years. He has a M.S and Ph.D., both in Cardiovascular Sciences with an emphasis on Cellular Signaling Transduction Pathways in multiple inflammatory disease states. He was NIH funded Fellow at Harvard Medical School/Brigham & Women’s Hospital, Center for Vascular Excellence before moving into Pharmaceuticals. At Actelion Pharmaceuticals, he started out as an MSL and then moved into multiple leadership roles within Field Medical Affairs and leading the Medical Science Liaison team. He moved to UCB Pharma to lead a regional MSL team, then quickly took on roles of increasing responsibilities such as National Director of Field Medical, Head of Medical Communications, earning several President Club Awards, and currently is the Field Medical Strategist & Head of MSLs, East US, for Rheumatology


Lubna Jamal
Real-World Evidence Consultant, PROGENICS PHARMACEUTICALS

view speaker profile

Dr. Jamal has been involved in clinical trials for more than 10 years and is currently consulting for Progenics, Pharmaceuticals. At Progenics, Pharmaceuticals she works with the planning, development, execution and reporting of clinical trials and real world evidence (RWE)/ big data trials. Prior to Progenics, she has for over 4 years of experience in the government and pharmaceutical industry at the national, regional and global levels. Through these experiences, she has built unique expertise in clinical development, and medical affairs in several disease areas. She possesses extensive clinical and scientific knowledge to ensure benchmarks are met in medical and pharmaceutical business environments. A passionate and visionary results-oriented leader with management experience in leading strategic, medical affairs, translational medicine, clinical development, legal, policy, and operations teams.
Dr. Jamal attended Howard University for her undergraduate studies subsequently did research on a collaborative project between Howard University and Johns Hopkins University entitled “Center for Reducing Asthma Disparities” for two years. She graduated from San Juan Bautista School of Medicine Caguas, Puerto Rico with a focus on community health and completed a Public Health Certificate in Maternal and Child Health at George Washington University. Furthermore, she completed a Master of Business Administration at George Washington University.


Daniel Jones
Senior Medical Director, Neurology & Immunology, EMD SERONO

view speaker profile

Daniel Jones, Ph.D., is Senior Medical Director, Neurology & Immunology at EMD Serono. In his current role, he serves as the US Medical Affairs launch lead for MAVENCLAD (Cladribine Tablets).

Danny joined EMD Serono in January 2018 from Biogen, where he held a number of Medical Director roles of increasing responsibility. Most recently, he served as the Global and US Medical Lead for MS Franchise & Pipeline. Prior to Biogen, Danny was an MSL in epilepsy and movement disorders at Lundbeck, where he served as the field medical lead for Onfi (clobazam).

Danny completed his Ph.D. at UCSF and his postdoctoral fellowship at Duke University Medical Center, where he was awarded grants from NIH and the Epilepsy Foundation; his research has been published in the Journal of Neurophysiology, Nature, and PNAS. He resides in Newton with his wife and four young children.


Peter Lee
Vice President, Chief Compliance Officer, HERON THERAPEUTICS

view speaker profile

Peter Lee received his B.A. from the University of Michigan and his J.D. from Quinnipiac Law School. He has a master’s in health law from Loyola University of Chicago and almost 20 years of experience building compliance programs in healthcare for hospitals, managed care organizations and pharmaceutical companies. He has held compliance and privacy officer positions at Sutter Health and Accenture, and has built compliance programs at Gilead Sciences, Hyperion Therapeutics and Pharmacyclics. He is currently Vice President of Compliance at Heron Therapeutics.


Robin LeWinter
Senior Director, Medical Communications, ORCHARD THERAPEUTICS

view speaker profile

Robin LeWinter obtained her PhD in Neuroscience from the University of California, San Francisco. Robin has over 15 years of experience in the field of Medical Communications at several small and mid-sized pharmaceutical companies. She is currently the Senior Director of Medical Communications at Orchard Therapeutics in Boston, MA, where she oversees and implements Orchard’s medical communication and publication strategy focusing on gene therapy platforms that treat rare diseases.


Barry Lubarsky, Ph.D.
Senior Medical Director, Medical Affairs, ALKERMES

view speaker profile

Barry Lubarsky is currently Senior Medical Director for Medical Affairs at Alkermes, Inc. where he is responsible for medical strategy and launch preparations for a novel drug combination under investigation for the treatment of major depressive disorder. Prior to Alkermes, Barry was at Ocular Therapeutix, Inc. where he led the build-out of the medical affairs group to support a pipeline and launch of innovative ophthalmic therapies. Before Ocular, Barry was at Vertex Pharmaceuticals Incorporated, where he led a medical director group that supported the launches of two personalized genetic medicines for the treatment of patients with cystic fibrosis. Barry also has medical affairs experience in the areas of hemophilia, inflammation, and dermatology. Barry holds a Ph.D. in Biochemistry from Stanford University.


Scott McConnell
Scientific Affairs Consultant, KALEIDO BIOSCIENCES

view speaker profile

Scott graduated with a Pharm.D. from Creighton University. He then completed a one-year Pharmacotherapy Residency and a two-year Infectious Diseases Fellowship. He served on faculty at both the University of Arkansas and Creighton University Pharmacy Schools, teaching infectious diseases and oncology with clinical practice sites in bone marrow transplantation, oncology/hematology and infectious disease. In 2006 he joined Cubist and remained at Cubist (acquired by Merck) until 2015. During his tenure at Cubist he spent time in a number of areas within medical affairs, including a number of leadership roles. Following Cubist worked at Chiasma and later at Alkermes (both as a Senior Director Medical Affairs) and was responsible for leading a number of areas within Medical Affairs. In 2019 he started consulting with Kaleido Biosciences building out their Scientific and Medical Affairs function and in July of 2019 he rejoined Chiasma as the VP of Medical Affairs and is currently rebuilding that function.


Michelle Ouellette
MSL, HERON THERAPEUTICS


Ray Pourfarzib, Ph.D.
Executive Director and TA Medical Lead Metabolics, ALEXION PHARMACEUTICALS

view speaker profile

Prior to joining Alexion as the Executive Director for the Metabolic MSL team, Dr. Pourfarzib was the Vice President of Clinical Affairs at LipoScience since 2007. In his senior leadership role at LipoScience, Ray’s responsibilities included clinical research development, publication, opinion leader development, and managed care account support in the cardiovascular/lipoprotein/lipid management. He also supported the development of the national advisory programs and speaker development programs.

He holds a Ph.D. in pharmacology from Mercer University in Atlanta, Georgia. His area of research focused on immunology, inflammation, lipid/lipoprotein metabolism and microencapsulated drug therapy.

Over the last 25 years, Dr. Pourfarzib has held a variety of positions in the pharmaceutical sector in Medical/Clinical Affairs divisions, Director of Managed Care team, Director of Regional Medical Liaison Team, and Executive Director of Disease Outcomes. These positions have allowed him to launch various products in chronic kidney disease, rheumatoid arthritis, psoriasis, hypertension, lipid metabolism and gastroenterology. Prior to joining LipoScience in 2007, Ray spent 6 years at Amgen leading their inflammation Regional Medical Liaison team and launching numerous biotechnology compounds and 7 years at AstraZeneca.

Dr. Pourfarzib has published over 70 papers and abstracts in number of academic journals throughout his career, including Atherosclerosis, American Journal of Gastroenterology, Journal of managed Care Pharmacy, and Journal of Pharmaceutical Research.


Azhar Rana
President, IMC NORTH AMERICA

view speaker profile

Dr. Azhar Rana is a physician with a broad clinical background, having trained in and practiced general medicine in the UK. In 2006, he joined the pharmaceutical industry and has worked in the UK, Denmark, Canada and the USA, holding several senior medical affairs positions across several therapy areas. In 2016, Dr. Rana and his team set up imc North America with the goal of providing innovation and excellence in communications to pharmaceutical and biotech organizations around the world. With a group of fantastic people, imc North America has become an award winning partner in the communications space, with a growing presence in Canada and the US


Kanchan Relwani, M.D.
Vice President, Medical Strategy, Medical Affairs, ALKERMES

view speaker profile

Kanchan Relwani, M.D., is currently Vice President Medical Strategy, Medical Affairs for Alkermes Inc. In this role, Kanchan is responsible for the Medical Affairs product strategies, as well as leading the field medical organization. Kanchan is an experienced Medical Affairs leader who has held positions of increasing responsibility, including heading the North American Medical Affairs group at Vertex Pharmaceuticals, and subsequently, leading the Medical Affairs and Clinical Teams at Stallergenes Greer. She has launched multiple products across different therapeutic areas and has a proven track record of leading successful, collaborative, cross-functional teams. Kanchan is an ophthalmologist by training and also has clinical research experience from UCL London, UK, and Harvard Medical School.


Daniel Snyder
Senior Director Medical Affairs, REVANCE THERAPEUTICS

view speaker profile

Daniel Snyder, PhD, is currently Executive Director, Clinical Development at Revance Therapeutics, Inc. Daniel is a synthetic organometallic chemist by formal training and has been in the pharmaceutical/medical device/biologics industry for 26-years post doctorate. He has held R&D and Medical Affairs leadership positions at Schering-Plough, Inc. (now Merk & Co., Inc.), Qualis, Inc., Coloplast, A/S, Talecris Biotherapeutics, Inc. (now Grifols, S.A.), Allergan, Inc. (now Allergan, PLC), Baxter International, Inc. (next Baxalta and now Shire) and Ipsen Biopharmaceuticals. The past 14 years of Daniel’s career has been in Medical Affairs.


Tyson Tu
Director and Head, Medical Communications, ALKERMES


Irene von Hennigs, Pharm.D.
Executive Director and TA Medical Lead Complement, Hematology and Nephrology, ALEXION PHARMACEUTICALS

view speaker profile

Irene started her education by earning a BA degree in Biology from the Notre Dame de Namur University in Belmont, CA and continued to earn a PharmD from Mercer University in Atlanta, GA. She then completed a pharmacy practice residency at the Johns Hopkins Hospital in Baltimore, MD.

She spent the last 24 years of her career in medical affairs in different roles and covering multiple therapeutic areas focusing on medical strategy and field operation excellence.

She is passionate about building and developing high performing medical teams. She has a strong background in medical recruitment, hiring, training and development, setting strategic goals and KOL relationship development. She is well recognized for her leadership skills and people management.

Prior to Alexion, she held a position as the Director of Clinical Science Managers at AbbVie supporting the men’s heath, gastroenterology, neurology and the metabolic franchises. In addition, Irene spent 11 years at AstraZeneca supporting the cardiovascular, nephrology franchises where she worked as a Product Development Scientist on a direct thrombin inhibitor, a dual PPAR agonist and an antiplatelet agent.

In her free time, Irene enjoys spending time with her husband and three teenagers boating, swimming, kayaking and paddle boarding. She also loves drinking her morning coffee with her


Courtney Zeni
Director of Medical Affairs, SUNOVION PHARMACEUTICALS

view speaker profile

Courtney is the Director of Medical Affairs at Sunovion Pharmaceuticals. Courtney recently joined the Sunovion team after 6 years at Noven Pharmaceuticals, Inc. as both a Medical Science Liaison and as the lead of the Medical Affairs department. Courtney’s passion within Medical Affairs is acting as the voice for patient/caregiver unmet need in order to develop medications that are safe, effective, and meaningful. Courtney has a great amount of experience with various pharmaceutical companies in publication planning, promotional review, content development, KOL identification/support, and advocacy outreach.

Courtney received her BS in Biology from The College of New Jersey and earned a PhD in Biochemistry and Molecular Biology from Rutgers University/UMDNJ. Through her academic research, Courtney received several honors including NIH Training grants, awards for poster and oral presentations, and invitations to speak at national conferences


Jenny Zhang
Associate Director, Portfolio and Strategy Launch Lead, Global Medical Affairs — Oncology, EMD SERONO


Steven Zhang
Vice President, Medical Affairs, KALA PHARMACEUTICALS